Anemia risk and mitigation strategies in type 2 diabetic patients:The role of novel antidiabetic agents  

作　　者：Petra Meliš Maja Cigrovski Berkovic 

机构地区：[1]Department for Endocrinology,Diabetes and Clinical Pharmacology,Clinical Hospital Dubrava,Zagreb 10000,Croatia [2]Department for Sport and Exercise Medicine,University of Zagreb Faculty of Kinesiology,Zagreb 10000,Croatia

出　　处：《World Journal of Diabetes》2025年第5期119-123,共5页世界糖尿病杂志(英文)

摘　　要：Anemia is a common yet often overlooked complication in patients with type 2 diabetes mellitus(T2DM),particularly those with chronic kidney disease.It significantly impacts patients'quality of life,cardiovascular health,and treatment outcomes.Despite its high prevalence,current clinical guidelines lack specific recommendations for anemia prevention and management in T2DM,especially in the context of newer antidiabetic therapies.This review explores the potential of emerging antidiabetic medications,such as sodium-glucose cotransporter-2 inhibitors,glucagon-like peptide-1 receptor agonists(GLP-1 RAs),and combined GLP-1-RA/GIP to mitigate anemia risk.Early detection and management of anemia in T2DM patients are crucial for improving glycemic control,reducing cardiovascular morbidity,and enhancing overall treatment outcomes.This review underscores the need for further research to better understand the mechanisms by which these novel therapies influence anemia risk and to integrate these findings into clinical practice.

关 键 词：ANEMIA Type 2 diabetes mellitus chronic kidney disease Iron deficiency METFORMIN Sodium-glucose cotransporter-2 inhibitors Glucagon-like peptide-1 receptor agonist Glucagon-like peptide-1 receptor agonist/GIP dual agonists 

分 类 号：R587.1[医药卫生—内分泌]